Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Graft-versus-host disease.

¹Division of Research Immunology/Bone Marrow Transplantation, Childrens Hospital of Los Angeles, California 90054.

Annual Review of Medicine

|January 1, 1991

Summary

This summary is machine-generated.

Graft-versus-host disease remains a major complication in bone marrow transplants. Chronic graft-versus-host disease incidence is unchanged despite improved chemoprophylaxis, and mismatched donors increase risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Study of thymic size and function in children and adolescents with treatment refractory systemic sclerosis eligible for immunoablative therapy.

Clinical immunology (Orlando, Fla.)·2009

Same author

Hematopoietic stem cell transplantation for severe combined immune deficiency.

Current allergy and asthma reports·2002

Same author

Detection of leukemic cells in the CD34(+)CD38(-) bone marrow progenitor population in children with acute lymphoblastic leukemia.

Blood·2001

Same author

T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency.

Archivum immunologiae et therapiae experimentalis·2000

Same author

Gene therapy for adenosine deaminase deficiency.

Annual review of medicine·2000

Same author

Spontaneous apoptosis in lymphocytes from patients with Wiskott-Aldrich syndrome: correlation of accelerated cell death and attenuated bcl-2 expression.

Blood·1999

Same journal

Dupilumab Emerges as an Effective Antibody Therapy for Eosinophilic Esophagitis.

Annual review of medicine·2026

Same journal

CAR T Cell Toxicities and Emerging Treatment Strategies.

Annual review of medicine·2026

Same journal

Transthyretin Amyloid Cardiomyopathy: A Rapidly Evolving Landscape.

Annual review of medicine·2026

Same journal

Accessibility of Somatic Genetic Testing for Cancer Treatment Decisions.

Annual review of medicine·2026

Same journal

Diffuse Parenchymal Lung Disease: Updates in Pathophysiology and Management.

Annual review of medicine·2026

Same journal

Revascularization for Ischemic Cardiomyopathy: Disproving the 45-Year-Old Concept of Hibernating Myocardium.

Annual review of medicine·2026

See all related articles

Area of Science:

Hematology
Immunology
Transplantation

Background:

Graft-versus-host disease (GVHD) is a significant complication following allogeneic bone marrow transplantation.
While acute GVHD incidence has decreased due to chemoprophylaxis, chronic GVHD rates persist.
Genotypic mismatch at the major histocompatibility complex (MHC) elevates both acute and chronic GVHD incidence.

Purpose of the Study:

To review the current status of graft-versus-host disease in bone marrow transplantation.
To discuss the impact of chemoprophylaxis on acute and chronic GVHD.
To highlight the role of donor matching in GVHD development.

Main Methods:

Review of existing literature on bone marrow transplantation and GVHD.
Analysis of trends in acute and chronic GVHD incidence.

Related Experiment Videos

Discussion of factors influencing GVHD, including donor-recipient matching and prophylaxis.

Main Results:

Improved chemoprophylaxis has lowered acute GVHD rates.
Chronic GVHD incidence has not been significantly affected by current prophylactic strategies.
Non-genotypically identical MHC donors are associated with increased GVHD incidence.

Conclusions:

Graft-versus-host disease, particularly the chronic form, remains a critical challenge in bone marrow transplantation.
Donor selection and matching are crucial for mitigating GVHD risk.
Further research is needed to improve prophylaxis and management of chronic GVHD.